Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 23, 2023

Acs Dobfar Company Profile

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the competitive landscape for ACS DOBFAR, and what generic and branded alternatives to ACS DOBFAR drugs are available?

ACS DOBFAR has twenty-three approved drugs.

Summary for Acs Dobfar

US Patents:	0
Tradenames:	14
Ingredients:	12
NDAs:	23

Drugs and US Patents for Acs Dobfar

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acs Dobfar	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INJECTION	065328-001	Jul 24, 2008	AP	RX	No	No		See Plans and Pricing				See Plans and Pricing
Acs Dobfar Spa	CEFOXITIN	cefoxitin sodium	INJECTABLE;INJECTION	065467-001	Aug 31, 2011		DISCN	No	No		See Plans and Pricing				See Plans and Pricing
Acs Dobfar	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INJECTION	065329-003	Jul 24, 2008	AP	RX	No	No		See Plans and Pricing				See Plans and Pricing
Acs Dobfar Spa	MEROPENEM	meropenem	INJECTABLE;INJECTION	204139-001	Jun 9, 2016	AP	RX	No	No		See Plans and Pricing				See Plans and Pricing
Acs Dobfar Spa	CEFOXITIN	cefoxitin sodium	INJECTABLE;INJECTION	065464-001	Aug 31, 2011		DISCN	No	No		See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Mallinckrodt

Harvard Business School

Johnson and Johnson

Boehringer Ingelheim

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.